Two cases of adult-onset de novo immunoglobulin A vasculitis with nephritis: Post-Covishield (ChAdOx1 nCoV-19; Oxford-Astra Zeneca) vaccination

With the ongoing worldwide COVID-19 vaccination programs, new-onset glomerular disease and relapse of the preexisting glomerular disease have been reported after COVID-19 vaccines administration. These incidences are overall very rare and had just temporal association with vaccination. It is, theref...

Full description

Saved in:
Bibliographic Details
Published inIndian journal of rheumatology Vol. 17; no. 3; pp. 294 - 299
Main Authors Jha, Vijoy, Akal, Ramanjit, Mahapatra, Debasish, Harikrishnan, S, Walia, Gurpreet
Format Journal Article
LanguageEnglish
Published Wolters Kluwer - Medknow Publications 01.07.2022
Medknow Publications and Media Pvt. Ltd
SAGE Publications
Subjects
Adults
B cells
covid-19 vaccine
glomerulonephritis
glucocorticoid
immuanoglobulin a vasculitis
Immunoglobulin A
Kidney diseases
purpura
Telmisartan
Vaccination
United Kingdom
immuanoglobulin A vasculitis
COVID-19 vaccine
glucocorticoid
glomerulonephritis
purpura
Online AccessGet full text

Cover

More Information
Summary:With the ongoing worldwide COVID-19 vaccination programs, new-onset glomerular disease and relapse of the preexisting glomerular disease have been reported after COVID-19 vaccines administration. These incidences are overall very rare and had just temporal association with vaccination. It is, therefore, the causal link with the COVID 19 vaccine is not firmly established. In this case-based review, we present two cases, who presented with purpuric rashes and joint pain between 2 and 3 weeks of 2nd dose of Covishield (ChAdOx1 nCoV-19; Oxford-Astra Zeneca) vaccination. Routine evaluation in both these cases revealed significant proteinuria and microscopic hematuria. The diagnosis of immunoglobulin A (IgA) vasculitis with nephritis was established with renal biopsy suggestive of IgA nephropathy and skin biopsy findings of leukocytoclastic vasculitis. Both these cases had severe renal involvement and responded to oral glucocorticoids after 8-16 weeks of treatment. Close observation and careful monitoring of these cases are required to determine the incidence of de novo or recurrence of glomerular disease postvaccination, the need for immunosuppressive therapy, response to aggressive treatment, and long-term clinical outcomes.
ISSN:0973-3698
0973-3701
DOI:10.4103/injr.injr_85_22